Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

In the News
Greg Scott presents industry update during JPMorgan
>> View video…

>> More News...

Now on Twitter!
 

Twitter ID: ChinaBio

International Big Pharma Continues China Investment

publication date: Nov 19, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Worldwide, big pharma may be retrenching, but it continues to invest in China. Because China’s drug market is young and growing, the country represents opportunity for these industry veterans, an opportunity that is made more attractive by their difficulties elsewhere. It’s not surprising, therefore, that several big pharmas have expressed their intention to enlarge their presence in China. Novartis, Novo Nordisk, GlaxoSmithKline, Bayer Schering and Bristol-Myers Squibb have each been in China biopharma news in recent days. More details...

Stock Symbols: (NYSE: NVS) (NYSE: NVO) (NYSE: GSK) (NYSE: BMY)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
ChinaBio® Events
April 14, 2010
Guangzhou, China

SEED Final Competion and Award Ceremony
April 23, 2010
Shanghai, China
Suzhou, China
June 23-24, 2010
 
Partner Events

China 2010 Pharmaceutical R&D Summit
Shanghai, China
April 5-8, 2010

Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners